Peritoneal dialysis in polycystic kidney disease patients
Introduction: Peritoneal dialysis (PD) in patients with polycystosis. Currently, it can be offered as a first-line treatment in these patients. The aim of our work is to analyse and compare the clinical and biological parameters, the evolution of residual renal function, technical survival and specific complications of PD in PKR subjects treated with PD compared to those without PKR and treated with the same supplementation technique.Patients and methods: Retrospective, observational study between July 2006 and October 2019 including 191 PD patients, 15 of whom had PKR.Results: The prevalence of PKR in PD is 8.9%. PKR is associated with a better quality of dialysis compared to the non-PKR group thanks to the persistence of RFR, it is also associated with a better technical (59 months versus 47 months) and patient (82 years versus 76 years) survival. Predictors of adequate dialysis are BMI <22 kg/m2 and persistence of residual renal function (RRF) after 3 years of PD. Hernias are more common in PKR patients (20%) but no predictive factors have been identified.Conclusion: PD can be offered as first-line therapy in PKR patients. A comparative study between PD and hemodialysis in PKR patients is necessary to demonstrate the value of PD in this population
2- Spithoven, E.M., Kramer, A., Meijer, E., et al., 2014. Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival—an analysis of data from the ERA-EDTA Registry. Nephrol. Dial. Transplant., 29(Suppl. 4):iv15-iv25.
3- Liu, et al. Nephrology in China. Nat. Rev. Nephrol.2013, 9(9): 523-528.
4-Abbott KC, Agodoa LY. Polycystic kidney disease at end-stage renal disease in the United States: patient characteristics and survival. Clin Nephrol 2002; 57: 208–14.
5- Harris PC, Hopp K. The mutation, a key determinant of phenotype in ADPKD. J Am Soc Nephrol. 2013; 24(6):868-870.
6-Hateboer N, v Dijk MA, Bogdanova N et al. Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1 PKD2 Study Group. Lancet 1999; 353: 103–107
7. Iglesias CG, Torres VE, Offord KP et al. Epidemiology of adult polycystic kidney disease, Olmsted County, Minnesota: 1935–1980. Am J Kidney Dis 1983; 2: 630-639
8. Gabow PA. Autosomal dominant polycystic kidney disease. N Engl J Med 1993; 329: 332–342
9- Liao C.T., Chen Y.M., Shiao C.C., et al: Rate of decline of residual renal function is associated with all-cause mortality and technique failure in patients on long-term peritoneal dialysis. Nephrol Dial Transpl 2009; 24: pp. 2909-2914
10- Kumar, S., Fan, S.L., Raftery, M.J., et al. Long term outcome of patients with autosomal dominant polycystic kidney diseases receiving peritoneal dialysis. Kidney Int, 2008. 74(7):946-951.
11-Yener Koc, Taner Basturk et al. Is peritoneal dialysis a therapeutic option for polycystic kidney disease. 15 years’ experience in a single center Néphrologie et Thérapeutique 2016 Volume 12, Issue 4, P:215-220
12- Janeiro, D., Portoles, J., Maria Tato, A., et al. Peritoneal dialysis can be an option for dominant polycystic kidney disease: an observational study. Perit. Dial. Int. 2015, 35(5): 530-536
13- Del Peso, G., Bajo, M.A., Costero, O., et al. Risk factors for abdominal wall complications in peritoneal dialysis patients. Perit. Dial. Int. 2003, 23(3):249-254.
14- M. Pierre, F. Toure et al. Comparaison de la survie technique de la dialyse péritonéale après réduction néphronique par néphrectomie en comparaison à l’embolisation artérielle rénale chez les patients polykystiques. Nephrologie et Therpeutique 2019 Vol 15 - N° 5 P. 267-268
15. Sharp CK, Zeligman BE et al. Evaluation of colonic diverticular disease in autosomal dominant polycystic kidney disease without end-stage renal disease. Am J Kidney Dis 1999; 34: 863–868
16- Dejardin A, Robert A, Goffin E. Intraperitoneal pressure in PD patients: relationship to intraperitoneal volume, body size and PDrelated complications. Nephrol Dial Transplant 2007; 22: 1437–1444
17- Sigone en al. Outcome of autosomal dominant polycystic kidney disease patients on peritoneal dialysis: a nation retrospective study based on two French registries (The French Language Peritoneal Dialysis Registry and the French Renal Epidemiology and Information Network; Nephrol Dial Transplant (2018)
18- Edwin M. Spithoven1, Anneke Kramer, et al Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival an analysis of data from the ERA-EDTA Registry. Nephrol Dial Transplant (2014)
19- Li, P.K., Szeto, C.C., Piraino, B., et al. Peritoneal dialysis-related infections recommendations: update. Perit. Dial. Int. 2010, 30(4):393-423.
Copyright (c) 2020 Hajar Benzouina
This work is licensed under a Creative Commons Attribution 4.0 International License.